{"id":"NCT04393441","sponsor":"Allergan","briefTitle":"Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease","officialTitle":"A Multicenter, Single-masked, Randomized Study to Compare the Efficacy and Safety of a New Artificial Tear Formulation (011516X) With Systane® Ultra Multidose for 90 Days in Participants With Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-29","primaryCompletion":"2021-06-15","completion":"2021-06-15","firstPosted":"2020-05-19","resultsPosted":"2024-06-26","lastUpdate":"2024-06-26"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease (DED)"],"interventions":[{"type":"DRUG","name":"011516X (New Artificial Tear Formulation)","otherNames":[]},{"type":"DRUG","name":"Systane Ultra Multidose","otherNames":[]},{"type":"DRUG","name":"REFRESH PLUS®","otherNames":["8197X"]}],"arms":[{"label":"Systane® Ultra Multidose","type":"ACTIVE_COMPARATOR"},{"label":"011516X (New Artificial Tear Formulation)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).","primaryOutcome":{"measure":"Change From Baseline in Total Staining Score at Day 90 in the Study Eye","timeFrame":"Baseline (Day 1) and Day 90","effectByArm":[{"arm":"Systane® Ultra Multidose","deltaMin":-4.5,"sd":0.4},{"arm":"011516X (New Artificial Tear Formulation)","deltaMin":-3.4,"sd":0.41}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0475"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":199},"commonTop":[]}}